Sandwich ELISA, Biotin-labelled antibody
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
n = 8; CV = 12.1%
n = 6; CV = 6.2%
- It is intended for research use only
- The total assay time is less than 3.5 hours
- The kit measures PON1 in serum and plasma (citrate)
- Assay format is 96 wells
- Standard is recombinant protein based
- Components of the kit are provided ready to use, concentrated or lyophilized
Cardiovascular disease, Energy metabolism and body weight regulation, Lipoprotein metabolism, Others
Paraoxonase 1 (PON1) is a member of a family of proteins that also includes PON2 and PON3, the genes for which are clustered in tandem on the long arms of human chromosome 7 (q21.22). PON1 belongs to a family of enzymes that catalyze the hydrolysis of a broad range of carboxylic acid esters, carbonates, and lactones, as well as toxic organophosphates, including the insecticide paraoxon.
PON1 is a 355 amino-acid glycoprotein, which is synthesized in the liver and secreted into the blood, where it associates with HDL (high-density lipoprotein). PON1 has a six bladed β-propeller structure reminiscent of DFPases (di-isopropylfluorophosphatases) with a unique active site lid.
PON1 has antioxidative properties, which are associated with the enzyme´s capability to protect LDL, as well as HDL from oxidation, to decrease macrophage oxidative status, to stimulate cholesterol efflux from macrophages, to decrease oxidative status in atherosclerotic lesions, and to attenuate atherosclerosis development.
Concentration and activity of PON1 are highly variable in human populations. PON1 levels can be modified by acquired factors such as diet, lifestyle and disease. A number of studies have shown that PON1 activity decreases with age. Cigarette smoke extract is known to inhibit PON1 activity and alcohol increases PON1 activity.
Most studies have found that PON1 activity is reduced in Type I and Type II diabetic patients. PON1 activity is also lower in patient with the metabolic syndrome, symptoms of which include abnormal fasting glucose levels and increased insulin resistance. Oxidative stress is a known risk factor for the development of dementia. PON1 activity is reportedly reduced in patients with vascular dementia and Alzheimer´s disease, however, it is not known if this is a cause or a consequence of increased oxidation.
Chronic renal failure is associated with elevated oxidative stress, and PON1 activity is consistently lower in patients suffering from renal failure. In one study, PON1 activity was restored to normal levels after kidney transplantation, suggesting that the effect on PON1 activity is a consequence of the disease and nota an underlying cause.
Alterations in PON1 activity have been seen in a number of others disorders, including liver cirrhosis, chronic hepatitis, HDL deficiencies, Gulf War Syndrome and anxiety.
Areas of investigation: Oxidative stress, Energy metabolism